scispace - formally typeset
I

Ian James

Researcher at Murdoch University

Publications -  220
Citations -  10983

Ian James is an academic researcher from Murdoch University. The author has contributed to research in topics: Human leukocyte antigen & Population. The author has an hindex of 43, co-authored 210 publications receiving 10228 citations. Previous affiliations of Ian James include King Edward Memorial Hospital & University of Western Australia.

Papers
More filters
Journal ArticleDOI

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

TL;DR: In this population of HIV-1-positive individuals, withholding abacavir in those with HLA-B*5701, H LA-DR7, and Hla-DQ3 should reduce the prevalence of hypersensitivity from 9% to 2.5% without inappropriately denying abacvir to any patient.
Journal ArticleDOI

Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level

TL;DR: A fundamental role is supported for HLA-restricted immune responses in driving and shaping HIV-1 evolution in vivo and at a population level the degree of HLA–associated selection in viral sequence was predictive of viral load.
Journal ArticleDOI

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

TL;DR: NRTIs do have an independent contribution to fat wasting, but PI are the predominant influence and may act synergistically with NRTIs, suggesting a non-linear decline in fat over time.
Journal ArticleDOI

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

TL;DR: The results of fine recombinant genetic mapping in an expanded patient population of 248 consecutive, fully ascertained, abacavir-exposed individuals in the Western Australian HIV Cohort Study indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacvir hypersensitivity.